Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma

Blood

Volumn 87, Issue 3, 1996, Pages 906-911

  Kuzel, Timothy M ^a   Hurria, Arti ^b   Samuelson, Ellen ^b   Tallman, Martin S ^b   Roenigk Jr , Henry H ^b   Rademaker, Alfred W ^b   Rosen, Steven T ^b  

^a NW Univ Feinberg School of Medicine   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; PURINE NUCLEOSIDE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; DEMOGRAPHY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; INFECTION COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; LABORATORY TEST; MALE; MYCOSIS FUNGOIDES; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEZARY SYNDROME; SKIN LYMPHOMA; T CELL LYMPHOMA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BONE MARROW DISEASES; CLADRIBINE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; OPPORTUNISTIC INFECTIONS; SEZARY SYNDROME; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0030065140     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.3.906.bloodjournal873906     Document Type: Article

References (18)

1. Weinstock MA, Horm JW: Mycosis fungoides in the United States - Increasing incidence and descriptive epidemiology. JAMA 260:42, 1988
2. Kuzel TM, Roenigk HH Jr, Rosen ST: Mycosis fungoides and the Sezary syndrome: A review of pathogenesis, diagnosis, and therapy. J Clin Oncol 9:1298, 1991
3. Kaye FJ, Bunn PA Jr, Steinberg SM: A randomized trial comparing combination electronic-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321.1784, 1989
4. Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 62:737, 1983
5. Tallman MS, Hakimian D, Variakojis D, et al: A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 80:2203, 1992
6. Hoffman M, Tallman MS, Hakimian D, et al: 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. J Clin Oncol 12:788, 1994
7. Piro LD, Carrera CJ, Beutler E, et al: 2-Chlorodeoxyadenosine: An effective new agent for the treatment of chronic lymphocytic leukemia. Blood 72:1069, 1988
8. Saven A, Carrera CJ, Carson DA, et al: 2-Chlorodeoxyadenosine: An active agent in the treatment of cutaneous T-cell lymphoma. Blood 80:587, 1992
9. O'Brien S, Kurzrock R, Duvic M, et al: 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood 844:733, 1994
10. Betticher DC, Fey MF, von Rohr A, et al: High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias. Ann Oncol 5:57, 1994
11. Bunn PA Jr, Lamberg SI: Report of the Committee on Staging and Classification of Cutaneous T-cell Lymphomas. Cancer Treat Rep 63:725, 1979
12. Grever MR, Bisaccia E, Scarborough DA, et al: An investigation of 2′deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood 61:279, 1983
13. Dang-vu AP, Olsen EA, Vollmer RT, et al: Treatment of cutaneous T-cell lymphoma with 2′-deoxycotbrmycin (Pentostatin). J Am Acad Dermatol 19:692, 1988
14. Cummings FJ, Kim K, Neiman RS, et al: Phase II trial of Pentostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol 9:565, 1991
15. Von Hoff DD, Dahlberg S, Hartstock RJ, et al: Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: A Southwest Oncology Group study. J Natl Cancer Inst 82:1353, 1990
16. Cheson BD, Vena DA, Foss FM, et al: Neurotoxicity of purine analogs: A review. J Clin Oncol 12:2216, 1994
17. Foss FM, Ihde DC, Breneman DL, et al. Phase II study of Pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. J Clin Oncol 10:1907, 1992
18. Foss FM, Ihde DC, Linnoila IR, et al: Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. J Clin Oncol 12:2051, 1994.